6657 — Energenesis Biomedical Co Cashflow Statement
0.000.00%
- TWD5.16bn
- TWD4.50bn
- TWD7.75m
Annual cashflow statement for Energenesis Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -129 | -120 | -266 | -260 | -231 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4.07 | 3.18 | 7.38 | 4.9 | 2.54 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 6.52 | -3.13 | 1.04 | 6.61 | 25 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -98.9 | -97.3 | -233 | -225 | -181 |
Capital Expenditures | -2.71 | -8.9 | -6.59 | -0.844 | -0.754 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 62.2 | -107 | 182 | -58.1 | 194 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 59.4 | -116 | 175 | -59 | 193 |
Financing Cash Flow Items | — | 0.127 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.77 | 288 | -1.75 | 440 | 145 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -34.7 | 74.9 | -59.2 | 156 | 158 |